Noxxon Pharma NV, of Berlin, said an unnamed top 10 international pharmaceutical company has signed an agreement with Noxxon for the purpose of evaluating NOX-A12 (olaptesed pegol) in a new indication, which will remain undisclosed for competitive reasons.